Provider of science services Thermo Fisher Scientific Inc (NYSE:TMO) has said that its COVID-19 diagnostic tests can accurately detect the new COVID-19 variant Omicron, Reuters news agency reported on Monday.
In a statement the company said that its TaqPath COVID-19 assays can report accurate results even in the case where one of the gene targets is impacted by a mutation.
Mark Stevenson, COO at Thermo Fisher Scientific, was quoted as saying in an interview: "This assay can be used not only to successfully detect COVID-19 but... it also be used as a proxy for the [Omnicron] variant."
Stevenson added that this is the only COVID-19 diagnostic test authorised by the US Food and Drug Administration and currently in use by health systems that can be used to indicate if a case is caused by the Omnicron variant.
Test samples must still be sent to a lab for sequencing to confirm that the case was caused by Omnicron and not another variant with similar features, such as the Alpha variant, Stevenson stated.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML